Doravirine/lamivudine/tenofovir
Combination drug for HIV
From Wikipedia, the free encyclopedia
Doravirine/lamivudine/tenofovir (DOR/3TC/TDF), sold under the brand name Delstrigo, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.[4][6] It contains doravirine, lamivudine, and tenofovir disoproxil.[7][6] It is taken by mouth.[4]
Tenofovir disoproxilNucleotide reverse transcriptase inhibitor
Trade namesDelstrigo
| Combination of | |
|---|---|
| Doravirine | Non-nucleoside reverse transcriptase inhibitor |
| Lamivudine | Nucleoside reverse transcriptase inhibitor |
| Tenofovir disoproxil | Nucleotide reverse transcriptase inhibitor |
| Clinical data | |
| Trade names | Delstrigo |
| Other names | MK-1439A |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618049 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
In the United States, it was approved by the Food and Drug Administration (FDA) for the treatment of HIV-1 infection in August 2018.[7][8][9]
